About | Free Trial

Last Update

2016-05-03T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong Cooper Collins?

Mr. Cooper Collins C.

Chairman and Chief Executive Officer

Fortis BioPharma

Fortis BioPharma

Company Description

Fortis BioPharma is a healthcare company primarily focused on developing and marketing ground breaking therapies that this generation of patients and consumers demand. The primary goal for Fortis is to develop natural options for patients first, when nece ... more

Find other employees at this company (1)

Background Information

Employment History

Biotech Hedge Fund Manager
SigmaBleyzer LLC

Director
TherapeuticsMD, Inc.

Affiliations

President and Chief Executive Officer
PERNIX THERAPEUTICS HOLDINGS, INC.

Education

B.A.

Nicholls State University

M.B.A.

Nicholls State University

Web References (196 Total References)


Cooper C. ...

www.sec.gov [cached]

Cooper C. Collins

...
Cooper C. Collins has served as a director of our company since February 2012. Mr. Collins has served as Chief Executive Officer of Fortis BioPharma since June 2015. Mr. Collins has served as Chief Strategy Officer of Pernix Therapeutics Holdings, Inc. [NASDAQ: PTX], or Pernix, from May 2013 until April 2014, as its President and Chief Executive Officer from March 2010 until May 2013, and as a director from March 2010 until February 2014. Pernix is a specialty pharmaceutical company focused on the sales, marketing, and development of branded and generic pharmaceutical products primarily for the pediatric market. Mr. Collins joined Pernix Therapeutics, Inc., a predecessor of Pernix, in 2002, where he was appointed as a director in January 2007, its President in December 2007, and its Chief Executive Officer in June 2008, serving in those three capacities until March 2010. From December 2005 to December 2007, Mr. Collins served as Vice President of Business and Product Development of Pernix Therapeutics, Inc. and as its Territory Manager from December 2003 to December 2005. Mr. Collins was employed for three years by the National Football League franchise, the New Orleans Saints, in its media relations department. We believe Mr. Collins’ specialty pharmaceutical company knowledge and executive experience provide the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. While on a football scholarship, Mr. Collins received a B.A. from Nicholls State University, where he later received an M.B.A.
...
Thompson, Carroll, Collins, LaPenta, Jr., Russell and Segal, is an independent director, as “independence” is defined under the applicable rules and regulations of the SEC and the listing standards of the NYSE MKT, because they do not have a relationship with us (either directly or as a partner, stockholder, or officer of an organization that has a relationship with us) that would interfere with their exercise of independent judgment in carrying out their responsibilities as directors.
...
LaPenta, Jr., Segal, Collins, and Russell, each an independent director of our company under the NYSE MKT rules as well as under rules adopted by the SEC
...
Collins, Thompson, and Carroll, with Mr. Collins serving as Chairman.
...
Collins, Thompson, and Carroll, with Mr. Collins serving as Chairman.
...
Collins, Thompson, and Carroll served as members of the Compensation Committee.
...
Collins, Thompson, or Carroll have been at any time one of our officers or employees or had any relationship with us that requires disclosure under Item 404 of Regulation S-K under the Exchange Act.


"When Fortis BioPharma decided ...

fortisbiopharma.com [cached]

"When Fortis BioPharma decided to create Naturmetic we did so with the consumer in mind, we imagined someone leading a healthy, fast paced lifestyle and naturally Korie fit the brand," said Cooper Collins, CEO of Fortis BioPharma.


Pernix | Pernix Therapeutics to Present at the Stifel Nicolaus Healthcare Conference

www.pernixtx.com [cached]

THE WOODLANDS, Texas-(BUSINESS WIRE)- Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company primarily focused on the pediatric market, today announced that Cooper Collins, President and Chief Executive Officer, will present at the Stifel Nicolaus Healthcare Conference on Wednesday, September 7, 2011 at 1:30 p.m. EDT.


Pernix | Pernix Therapeutics Expands Senior Management Team to Support Continued Business Growth

www.pernixtx.com [cached]

"I am pleased to welcome David, Chuck and Leslie to Pernix," said Cooper Collins, President and Chief Executive Officer of Pernix.


Source: Perniz Therapeutics Holdings 10K ...

www.private2ipo.com [cached]

Source: Perniz Therapeutics Holdings 10K "Cooper Collins, President and CEO of Pernix, said, "This will be the most significant acquisition in the Company's history.

Similar Profiles

Other People with this Name

Other people with the name Collins

Clive Collins
HOB Salons

Lucy Collins
Oldham College

Molly Collins
Maine Coast Memorial Hospital

Steven Collins
Advent International Corporation

Michael Collins
Sertoma Centre Inc

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory